CRISPR & Cas Genes Market Outlook 2031
The global CRISPR & cas genes market size was valued at USD 2.09 Billion in 2022 and is expected to surpass USD 7.75 Billion by 2031, expanding at a CAGR of 15.67% during the forecast period, 2023–2031. The growth of the market is attributed to its increased use in several domains of biotechnology, such as epigenetics and medicine, human germline editing, and a tool for qualitative and quantitative plant genome editing.
CRISPR-cas techniques are powerful nucleic acid-targeting technologies that are simple to program. Its applications span from research and drug discovery to precision breeding of plants and animals and industrial microbial engineering.
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a gene editing method. CRISPR-cas is a significant breakthrough in biological science. It offers the potential to cure rare diseases in a variety of contexts. Researchers use this technology to change elements of the genome by adding, changing, or removing sections of the DNA sequence.
Many patients undergoing CRISPR-Cas gene therapy are being monitored and are waiting for FDA approval. The CRISPR-Cas system is a prokaryotic immune system that enables acquired immunity by conferring resistance to exogenous genetic elements.
It is faster, more efficient, and more precise than previous DNA modification techniques, and it has a wide range of possible uses. Crop breeding, biotechnology and pharmaceutical businesses, microbial engineering, and genome engineering all use this method.
CRISPR & Cas Genes Market Trends, Drivers, Restraints, and Opportunities
- Increasing number of strategic collaborations between market players is projected to boost the market during the forecast period.
- Rising funding and investments in gene editing technologies is expected to promote the growth of the market during the forecast period.
- Development of CRISPR technologies is anticipated to boost the market.
- Increasing incidence of genetic disorders is expected to fuel the market during the forecast period.
- Rising ethical and safety issues regarding CRISPR technologies is expected to hinder the market growth during the forecast period.
- Availability of alternatives of CRISPR & cas genes is anticipated to hamper the market expansion in the coming years.
Increasing number of clinical trials using CRISPR technology to develop treatments for diseases such as thalassemia, sickle cell disease, myeloma, solid tumors, and hematologic malignancies, diabetes, and others, is expected to create opportunities for the market players.
Scope of CRISPR & Cas Genes Market Report
The report on the global CRISPR & cas genes market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
CRISPR & Cas Genes Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Products (Vector-based Cas and DNA-free Cas), Applications (Genome Engineering, Disease Models, Functional Genomics, and Others), End-users (Biotechnology & Pharmaceutical Companies, Academics & Government Research Institutes, and Contract Research Organizations)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
OriGene Technologies, Inc., Thermo Fisher Scientific, Takara Bio Inc, Horizon Discovery Ltd., Addgene, Merck KGaA, Caribou Biosciences, Inc., CRISPR THERAPEUTICS, Editas Medicine, and Mirus Bio LLC
CRISPR & Cas Genes Market Segment Insights
Product Segment Analysis
Based on products, the CRISPR & cas genes market is divided into vector-based cas and DNA-free cas. The vector-based cas segment is anticipated to dominate the market during the forecast period. Medical researchers focusing on Cas9 enrichment benefit from vector-based cas systems. A promoter is usually included in the vector-based cas, allowing stable cell lines to be created.
Application Segment Analysis
In terms of applications, the global CRISPR & cas genes market is segregated into genome engineering, disease models, functional genomics, and others. The genome engineering segment is anticipated to dominate the market during the forecast period.
To generate genomic engineering, natural genomic sequences are coupled with a synthetic assembly of entire chromosomal DNA. The method allows for the addition, modification, or removal of genetic material from specified genomic sites. For the foreseeable future, extensive biomedical research is expected to propel the market.
End-users Segment Analysis
On the basis of end users, the global CRISPR & cas genes market is segregated into biotechnology & pharmaceutical companies, academics & government research institutes, and contract research organizations. The biotechnology and pharmaceutical companies segment is anticipated to dominate the market during the forecast period.
The segment is being fueled by the rising adoption of CRISPR technology by prominent biotechnology and pharmaceutical companies. Companies are increasingly turning to CRISPR-Cas9 to generate biological models for human diseases in less time and to speed up the discovery and validation of new therapeutic targets.
On the basis of regions, the global CRISPR & cas genes market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market at a high CAGR during the forecast period.
Factors such as the existence of significant companies, increased spending in biotechnology and genomics programs, and developed healthcare infrastructure are some of the primary factors responsible for the large share of the market in North America.
- Vector-based Cas
- DNA-free Cas
- Genome Engineering
- Disease Models
- Functional Genomics
- Biotechnology & Pharmaceutical Companies
- Academics & Government Research Institutes
- Contract Research Organizations
- Asia Pacific
- North America
- Europe, Latin America
- Middle East & Africa
- OriGene Technologies, Inc.
- Thermo Fisher Scientific
- Takara Bio Inc
- Horizon Discovery Ltd.
- Merck KGaA
- Caribou Biosciences, Inc.
- CRISPR THERAPEUTICS
- Editas Medicine
- Mirus Bio LLC
The global CRISPR and CRISPR-associated (Cas) genes market is relatively consolidated, with only a few prominent competitors. OriGene Technologies, Inc., Thermo Fisher Scientific, Takara Bio Inc, Horizon Discovery Ltd., Addgene, Merck KGaA, Caribou Biosciences, Inc., CRISPR THERAPEUTICS, Editas Medicine, and Mirus Bio LLC are some of the key companies in the market.